CRIS Current Research Information System

PICCALUGA, PIER PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.066
EU - Europa 12.284
AS - Asia 8.863
AF - Africa 675
SA - Sud America 675
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 6
Totale 35.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.953
IT - Italia 4.242
CN - Cina 2.963
SG - Singapore 2.855
GB - Regno Unito 2.653
DE - Germania 1.228
SE - Svezia 1.218
VN - Vietnam 1.166
HK - Hong Kong 654
IN - India 576
UA - Ucraina 565
RU - Federazione Russa 562
BR - Brasile 489
FR - Francia 433
IE - Irlanda 365
ZA - Sudafrica 255
NL - Olanda 215
EE - Estonia 173
TG - Togo 169
CH - Svizzera 155
JP - Giappone 147
CI - Costa d'Avorio 141
KR - Corea 129
FI - Finlandia 107
IR - Iran 80
AR - Argentina 79
JO - Giordania 73
CA - Canada 71
BG - Bulgaria 62
ID - Indonesia 61
BE - Belgio 54
SC - Seychelles 43
GR - Grecia 39
EC - Ecuador 35
TR - Turchia 32
PL - Polonia 31
HR - Croazia 27
MX - Messico 27
NG - Nigeria 27
ES - Italia 26
LU - Lussemburgo 24
AT - Austria 22
CL - Cile 22
BD - Bangladesh 21
LB - Libano 20
RO - Romania 20
IQ - Iraq 16
PY - Paraguay 15
CO - Colombia 14
AU - Australia 9
LT - Lituania 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
TN - Tunisia 8
AL - Albania 7
EG - Egitto 7
PE - Perù 7
SK - Slovacchia (Repubblica Slovacca) 7
UY - Uruguay 7
CZ - Repubblica Ceca 6
MY - Malesia 6
NZ - Nuova Zelanda 6
PH - Filippine 6
PK - Pakistan 6
PT - Portogallo 6
DZ - Algeria 5
HU - Ungheria 5
IL - Israele 5
KZ - Kazakistan 5
RS - Serbia 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
CR - Costa Rica 3
IS - Islanda 3
KE - Kenya 3
KG - Kirghizistan 3
MA - Marocco 3
MD - Moldavia 3
NP - Nepal 3
SA - Arabia Saudita 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
EU - Europa 2
HN - Honduras 2
NE - Niger 2
SI - Slovenia 2
TW - Taiwan 2
UG - Uganda 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CM - Camerun 1
Totale 35.562
Salva come PNG Salva come JPEG
Città #
Southend 2.359
Singapore 1.818
Fairfield 1.583
Ashburn 1.345
Chandler 930
Houston 789
Woodbridge 759
Seattle 714
Wilmington 703
Hong Kong 646
Cambridge 576
Princeton 575
Ann Arbor 518
Santa Clara 451
Dong Ket 450
Beijing 419
Milan 404
Dublin 356
Hefei 338
Boardman 305
Rome 304
Jacksonville 299
Bologna 269
Nanjing 267
Padova 254
Westminster 238
Lomé 168
Ho Chi Minh City 161
Los Angeles 158
Abidjan 141
Jinan 137
Tokyo 137
New York 135
Berlin 131
Shenyang 131
Saint Petersburg 127
Seoul 122
Turin 120
Hanoi 119
Bern 118
Naples 116
Bremen 110
Buffalo 108
Hebei 107
Changsha 89
Nanchang 86
Helsinki 85
Mülheim 82
Florence 79
Redondo Beach 78
San Diego 77
Amman 73
Dallas 70
Tianjin 66
Parma 64
Sofia 61
Guangzhou 60
Medford 60
Jiaxing 56
São Paulo 53
Brussels 50
Verona 48
Zhengzhou 48
Hangzhou 45
Frankfurt am Main 44
Hyderabad 44
Haikou 42
Shanghai 42
Falls Church 41
Redwood City 40
Bengaluru 38
Munich 38
Taizhou 38
London 37
Phoenix 37
Dearborn 35
Yubileyny 35
Ningbo 34
Palermo 34
Taiyuan 34
Mahé 33
San Venanzo 32
Toronto 32
Cagliari 31
Norwalk 29
Olalla 29
Jakarta 28
Bari 26
Chicago 26
Fuzhou 26
Catania 25
Wuhan 25
Abeokuta 24
Falkenstein 23
Amsterdam 21
Brescia 21
Como 21
Nuremberg 21
Pavia 20
Redmond 20
Totale 22.471
Salva come PNG Salva come JPEG
Nome #
Linfomi non Hodgkin di derivazione dai linfociti T-periferici. 1.827
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 731
Linfomi non Hodgkin di derivazione dai linfociti T-periferici. 551
Leucemia Acuta Linfoide. 458
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 280
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 266
Biology and treatment of follicular lymphoma. 264
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 233
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 226
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 221
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 211
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 208
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 208
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 207
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 206
Advances in the treatment for haematological malignancies. 204
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 203
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 200
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 199
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 198
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 196
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 196
IFI16 expression is related to selected transcription factors during B-cell differentiation 196
Expression of CD52 in peripheral T-cell lymphoma. 192
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. 191
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 191
Conditioning regimens in acute myeloid leukemia. 185
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 184
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome 183
Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation 181
FIRMA MOLECOLARE E SUOI USI COME AGENTE DIAGNOSTICO 178
Epstein-Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas 178
Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy 175
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 172
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 170
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 170
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 168
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 168
Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma 167
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 167
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 167
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 166
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 165
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 164
Pathobiologic Roles of Epstein-Barr Virus-Encoded MicroRNAs in Human Lymphomas 164
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 163
MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES 163
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients 162
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 161
BCL10 down-regulation in peripheral T-cell lymphomas. 160
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma 159
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 159
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 159
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas 158
SNPs Array Karyotyping in Non-Hodgkin Lymphoma 158
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 157
Pathobiology of hodgkin lymphoma. 157
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 156
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 156
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. 155
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 155
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 155
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 155
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. 154
MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma 154
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. 154
Duplex real-time polymerase chain reaction assay for the detection of human KIPyV and WUPyV in nasopharyngeal aspirate pediatric samples 153
Linfomi non Hodgkin di derivazione dai linfociti T-periferici primitivi della cute. 152
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 152
Molecular genetics of peripheral T-cell lymphomas 152
Clonality analysis of immunoglobulin gene rearrangement by next-generation sequencing in endemic burkitt lymphoma suggests antigen drive activation of bcr as opposed to sporadic burkitt lymphoma 152
Molecular profiling of aggressive lymphomas 151
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 151
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 150
Pathobiology of anaplastic large cell lymphoma. 150
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 148
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 148
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 147
Unveiling another missing piece in EBV-driven lymphomagenesis: EBV-encoded microRNAs expression in EBER-negative Burkitt lymphoma cases 147
Targeted molecular therapy in peripheral T-cell lymphomas 146
The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis 144
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 144
The cell of origin of Burkitt lymphoma: germinal centre or not germinal centre? 144
The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. 143
Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas 141
Pathobiology of ALK-negative anaplastic large cell lymphoma. 141
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 141
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 141
Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing 141
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 140
Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. 139
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 139
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 138
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 138
Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia 137
Prognostic markers in peripheral T-cell lymphoma. 136
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 136
Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. 136
Single-Step IGHV Next-Generation Sequencing Detects Clonality and Somatic Hypermutation in Lymphoid Malignancies: A Phase III Diagnostic Accuracy Study 134
Totale 19.912
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.880
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.231 0 0 0 0 0 209 79 174 377 209 195 988
2021/20224.470 353 178 292 365 443 293 95 280 225 373 909 664
2022/20235.150 641 704 254 655 313 385 164 266 866 141 456 305
2023/20242.205 124 248 121 172 151 299 172 179 91 187 199 262
2024/20255.472 325 876 480 416 834 294 580 204 105 262 169 927
2025/20265.814 761 921 1.105 1.047 1.388 592 0 0 0 0 0 0
Totale 36.218